DDInter825 DDInter1729
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Glimepiride {u} (Compound) causes {v} (Side Effect) Stevens-Johnson syndrome
Stevens-Johnson syndrome {u} (Side Effect) is caused by {v} (Compound) Sulindac
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clomipramine
Clomipramine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Sulindac
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Sulindac
Glimepiride {u} may lead to a major life threatening interaction when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Glimepiride {u} may lead to a major life threatening interaction when taken with {v} Norfloxacin
Norfloxacin {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sulindac
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Glimepiride (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Sulindac (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sulindac (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sulindac (Compound)
Glimepiride may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Glimepiride may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sulindac (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)